Načítá se...
CYP2D6 haplotypes with enhancer SNP rs5758550 and rs16947 (*2 allele): implications for CYP2D6 genotyping panels
CYP2D6 metabolizes ~25% of all clinically used drugs, with numerous genetic polymorphisms affecting enzyme activity and drug response. Clinical utility of current CYP2D6 genotyping is partially compromised the unresolved complex haplotype structure of the CYP2D6 locus. We have identified a distal en...
Uloženo v:
| Vydáno v: | Pharmacogenet Genomics |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6441960/ https://ncbi.nlm.nih.gov/pubmed/30520769 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0000000000000363 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|